Creating a new vaccine approach for treating oral melanoma in dogs.
Official title: Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.
Funded at University of Minnesota · NIH-10997318 · Data updated 2026-11-12
This study is testing a new vaccine for dogs with oral melanoma, a type of cancer, to see if it can help their immune system fight the disease better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | December 8, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $439,339 |
| NIH project number | 5R01CA285620-02 |
| Project ID | NIH-10997318 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are dogs diagnosed with oral melanoma.
✕Less likely to help
Dogs with other types of cancer or those not diagnosed with oral melanoma may not benefit from this research.
What this research studies
This research focuses on developing a novel vaccine strategy using adeno-associated virus (AAV) vectors to stimulate the immune system against oral melanoma, a type of cancer affecting dogs. The team aims to optimize these AAV vectors to effectively deliver cancer antigens, enhancing the body's immune response. By conducting preclinical studies in companion dogs, the research seeks to evaluate the safety and effectiveness of these vaccines, potentially leading to improved cancer treatments. The project also investigates the interactions between AAV vectors and the immune system to maximize therapeutic outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies for oral melanoma in dogs, improving survival rates and quality of life.
How similar studies have gone: Other research has shown promise in using AAV vectors for cancer immunotherapy, indicating potential for success in this novel approach.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Aslanidi, George V — University of Minnesota
- Study coordinator: Aslanidi, George V
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.